@phdthesis{oai:ir.kagoshima-u.ac.jp:00015485,
 author = {横田, 璃里 and Yokota, Riri},
 month = {2022-08-09, 2021-08-04, 2020-10-05, 2020-10-05},
 note = {博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨, Background/Aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity. Materials and Methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay. Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells. Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL.

RIRI YOKOTA, SHUN HASHIMOTO, IKUKO WATANABE, SATOSHI KISHIMOTO, MASAAKI TOYAMA, MIKA OKAMOTO, MAKOTO YOSHIMITSU, KENJI ISHITSUKA, YUJI ITO and MASANORI BABA
Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)
Anticancer Research 40(8): 4471-4479 (2020)
https://doi.org/10.21873/anticanres.14452},
 school = {鹿児島大学},
 title = {Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)},
 year = {},
 yomi = {ヨコタ, リリ}
}